Bristol-Myers Squibb reported fourth-quarter results and issued 2023 guidance that ran a bit higher than our expectations, but we don’t expect any major changes to our fair value estimate based on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback